Boston Scientific Corp (NYSE:BSX) stock rose 0.15% (As on October 23, 11:40:26 AM UTC-4, Source: Google Finance) after the company raised its full-year guidance as the medical device supplier’s third-quarter results came in stronger than Wall Street’s estimates, driven by a 22% revenue surge in its cardiovascular segment. Third-quarter sales in the cardiovascular business surged 22% year over year to $3.34 billion, driven by a 24% advance in cardiology. The MedSurg division jumped 16% to $1.72 billion amid double-digit gains in endoscopy and urology. The company logged revenue growth across all the regions it operates in, including a 27% rise in the US.
Meanwhile, the company has recently announced it has entered into a definitive agreement to acquire Nalu Medical, Inc., a privately held medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic pain. Boston Scientific expects to complete the transaction in the first half of 2026, subject to customary closing conditions. Nalu is expected to generate sales in excess of $60 million in 2025 and to deliver year-over-year growth in excess of 25% in 2026. In addition, the company had announced Pharmaceuticals and Medical Device Agency (PMDA) approval in Japan for expanded labeling of the FARAPULSE Pulsed Field Ablation (PFA) System to include treatment of drug refractory, symptomatic persistent atrial fibrillation (AF).
BSX in the third quarter of FY25 has reported the adjusted earnings per share of 75 cents, beating the analysts’ estimates for the adjusted earnings per share of 71 cents. The company had reported the adjusted revenue growth of 20.3 percent to $5.07 billion in the third quarter of FY25, beating the analysts’ estimates for revenue of $4.97 billion. It rose 19.4 percent on an operational basis; and 15.3 percent on an organic basis.
The company now expects adjusted earnings between $3.02 and $3.04 per share for 2025, up from up from its prior estimate of $2.95 to $2.99. Sales are pegged to grow about 20% on a reported basis, compared with the previous forecast of 18% to 19%. Analysts surveyed by FactSet expect non-GAAP EPS of $2.98 on sales of $19.88 billion, up from last year’s $2.51 and $16.75 billion, respectively.
For the current quarter, the biotech firm expects adjusted EPS of $0.77 to $0.79 on sales growth of 14.5% to 16.5%. Analysts are looking for non-GAAP EPS of $0.76 on sales of $5.18 billion. The revenue outlook for the December quarter excludes an approximately 200-basis-point tailwind from foreign exchange